Search

everythinglearnresearchcommunity

for

Search:↓

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

Using a call center to collect data in a trial for eye disease in diabetics led to high response rates and very little missing information.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Age, hair loss duration, menopause, and specific treatments affect hair density and caliber in female hair loss patients.

Prolactin affects hair growth and skin conditions, and could be a target for new skin disease treatments.

People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.

Patients with certain skin diseases are willing to spend significant time on treatment, indicating a high impact on their lives and a need for better treatments.

Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.

Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.

Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.

Patients with cutaneous lupus are most concerned about self-consciousness, physical symptoms, and disease progression.

Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.

Alopecia areata and androgenetic alopecia affect quality of life similarly.

People with psoriasis and depression have lower BDNF levels, which could help measure depression in those with psoriasis.

Hair loss lowers quality of life, causing embarrassment, frustration, and sexual rejection.

People with certain skin diseases have higher levels of the hormone prolactin in their blood.

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

Alopecia areata causes hair loss, has no cure, and various treatments exist.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Some skin conditions may indicate metabolic syndrome, which could help with early detection and management of related health issues.

Severe vertex pattern hair loss may indicate a higher risk for artery plaque buildup.

Patients with oral lichen planus or oral lichenoid reactions had worse cholesterol levels and a higher risk of obesity compared to healthy individuals.

Certain health conditions and hair care habits affect the treatment results for a scalp condition called Central Centrifugal Cicatricial Alopecia.

Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.

People with Alopecia Areata often have thyroid problems like Hashimoto thyroiditis and hypothyroidism.

Higher EULAR/ACR scores in SLE patients predict more organ damage.

Psoriasis, acne, and hair loss are linked to unhealthy cholesterol levels, increasing heart disease risk.

APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.

The study suggests smoking is common in HS patients but its role is unclear, and more research is needed to understand HS causes.